Elena A. Dondurey
Research Subjects
Research Interests
Elena A. Dondurey has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Alla A. Vilnits
Federal Research and Clinical Center for Infectious Diseases; Saint Petersburg State Pediatric Medical University
2 shared publications - Ilia S. Avrusin
St. Petersburg State Pediatric Medical University
2 shared publications - Konstantin E. Belozerov
St. Petersburg State Pediatric Medical University
2 shared publications - Mikhail Mikhaylovich Kostik
St. Petersburg State Pediatric Medical University
2 shared publications - Tatiana L. Kornishina
Saint Petersburg State Pediatric Medical University
2 shared publications - Vera Vasilyevna Masalova
St. Petersburg State Pediatric Medical University
2 shared publications
Latest Publications
- Open Access
- 27 December 2024
- Published by SPRIDA in Journal Infectology
- Vol. 16 (4) , 112-121
Innovations in the treatment and prevention of influenza in children and adolescents
In September 2024, an Expert Council via videoconference was held to discuss innovative approaches to the tactics of diagnosis and therapy of influenza in children and adolescents in Russian Federation.Influenza is characterized by high morbidity and mortality, leading to 28,000 deaths annually worldwide among children.Influenza causes significant economic damage, ranking 4th among all infectious diseases in 2023 in Russian Federation. During the 20222023 period, there was an increase in influenza incidence with a traditionally high rate of infection among children. Newborns, children under 5 years old, and children with comorbidities are at high risk for complications. An analysis of influenza mortality shows that comorbidity is an aggravating factor in almost half of the cases.Timely diagnosis and etiotropic therapy are key in the treatment of influenza. The focus should be on etiological confirmation of the diagnosis within the first 24 hours from disease manifestation to prescribe specific antiviral therapy. Although laboratory confirmation of the diagnosis is recommended, during periods of high incidence, the diagnosis can be made based on clinical and epidemiological data. For final verification of the “influenza” diagnosis, the widespread use of certified rapid tests is proposed.According to the updated WHO guidelines published in September 2024, two medicines are recommended for the treatment of influenza — baloxavir and oseltamivir. Baloxavir marboxil significantly reduces the virus shedding time and has a favorable safety profile for children and adolescents. This makes it the medicine of choice, especially in cases of high risk of complicated influenza infection.Given the high importance of influenza in the structure of childhood morbidity, it is crucial to continue improving methods of prevention, diagnosis, and treatment of this disease, especially in children.
- 27 December 2024
- Published by SPRIDA in Journal Infectology
- Vol. 16 (4) , 112-121
Open AccessInnovations in the treatment and prevention of influenza in children and adolescents
In September 2024, an Expert Council via videoconference was held to discuss innovative approaches to the tactics of diagnosis and therapy of influenza in children and adolescents in Russian Federation.Influenza is characterized by high morbidity and mortality, leading to 28,000 deaths annually worldwide among children.Influenza causes significant economic damage, ranking 4th among all infectious diseases in 2023 in Russian Federation. During the 20222023 period, there was an increase in influenza incidence with a traditionally high rate of infection among children. Newborns, children under 5 years old, and children with comorbidities are at high risk for complications. An analysis of influenza mortality shows that comorbidity is an aggravating factor in almost half of the cases.Timely diagnosis and etiotropic therapy are key in the treatment of influenza. The focus should be on etiological confirmation of the diagnosis within the first 24 hours from disease manifestation to prescribe specific antiviral therapy. Although laboratory confirmation of the diagnosis is recommended, during periods of high incidence, the diagnosis can be made based on clinical and epidemiological data. For final verification of the “influenza” diagnosis, the widespread use of certified rapid tests is proposed.According to the updated WHO guidelines published in September 2024, two medicines are recommended for the treatment of influenza — baloxavir and oseltamivir. Baloxavir marboxil significantly reduces the virus shedding time and has a favorable safety profile for children and adolescents. This makes it the medicine of choice, especially in cases of high risk of complicated influenza infection.Given the high importance of influenza in the structure of childhood morbidity, it is crucial to continue improving methods of prevention, diagnosis, and treatment of this disease, especially in children.
- Open Access
- 18 April 2023
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (1) , 45-59
The predictors of severe course of multisystem inflammatory syndrome associated with the new coronavirus infection COVID-19 in children: results of a retrospective-prospective multicenter study
BACKGROUND:Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a rare but severe disease in which various organs and systems are affected, including heart, lungs, kidneys, brain, skin, eyes and organs of the gastrointestinal tract. MIS-C is rather difficult to diagnose, since it has much in common with the infectious process, and Kawasaki disease. However, MIS-C course is more severe and therefore patients need hospitalization in the intensive care unit in half of the cases. AIM:To determine the factors associated with severe course of MIS-C, requiring hospitalization of patients in the intensive care unit. MATERIALS AND METHODS:The retrospective study included 166 patients (99 boys, 67 girls), aged 4 months to 17 years (median 8.2 years), with a diagnosis of multisystem inflammatory syndrome associated with COVID-19 in children. To conduct a comparative analysis, patients with MIS-C were divided into two groups: group 1 patients hospitalized in the intensive care unit (n= 84, 50.6%), and group 2 patients who did not need hospitalization in the intensive care unit (n= 82, 49.4%). RESULTS:Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin and D-dimer levels. Also, in patients hospitalized in the intensive care unit, signs of hemophagocytic syndrome were more often observed. CONCLUSIONS:The main factors determining the severity of MIS-C are damage to the cardiovascular system, the central nervous system, the presence of respiratory and hemodynamic disorders, especially hemophagocytosis.
- 18 April 2023
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (1) , 45-59
Open AccessThe predictors of severe course of multisystem inflammatory syndrome associated with the new coronavirus infection COVID-19 in children: results of a retrospective-prospective multicenter study
BACKGROUND:Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a rare but severe disease in which various organs and systems are affected, including heart, lungs, kidneys, brain, skin, eyes and organs of the gastrointestinal tract. MIS-C is rather difficult to diagnose, since it has much in common with the infectious process, and Kawasaki disease. However, MIS-C course is more severe and therefore patients need hospitalization in the intensive care unit in half of the cases. AIM:To determine the factors associated with severe course of MIS-C, requiring hospitalization of patients in the intensive care unit. MATERIALS AND METHODS:The retrospective study included 166 patients (99 boys, 67 girls), aged 4 months to 17 years (median 8.2 years), with a diagnosis of multisystem inflammatory syndrome associated with COVID-19 in children. To conduct a comparative analysis, patients with MIS-C were divided into two groups: group 1 patients hospitalized in the intensive care unit (n= 84, 50.6%), and group 2 patients who did not need hospitalization in the intensive care unit (n= 82, 49.4%). RESULTS:Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin and D-dimer levels. Also, in patients hospitalized in the intensive care unit, signs of hemophagocytic syndrome were more often observed. CONCLUSIONS:The main factors determining the severity of MIS-C are damage to the cardiovascular system, the central nervous system, the presence of respiratory and hemodynamic disorders, especially hemophagocytosis.
- Open Access
- 18 April 2023
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (1) , 35-43
Hemostasis in children with COVID-19-RELATED illness
BACKGROUND:During the COVID-19 pandemic, the problem of coronavirus-associated coagulopathy was one of the most difficult and poorly studied. The detected hemostasis disorders in adults are extrapolated to children and adolescents without sufficient representation in the literature. Because of COVID-19 is generally told as a mild disease in children a detailed laboratory examination not required. As a result, thrombotic and hemorrhagic complications, as well as the childrens multisystem inflammatory syndrome (MIS-C) are unexpected. At the same time, the hemostasis assessment in children with COVID-19 is necessary for the coronavirus-associated coagulopathy timely diagnosis, adequate anticoagulant therapy prescribing, various convalescence thrombotic complications prevention, as well as determining the necessary period of dynamic monitoring of patients. AIM:To assess the hemostasis in children with COVID-19-related illness in the acute disease period and convalescence. MATERIALS AND METHODS:The results of the examination of 460 patients from 2 days to 18 years old hospitalized with confirmed SARS-CoV-2 infection and 110 outpatient children from 3 months to 17 years old at different periods of COVID-19 convalescence are presented. The study included platelet count measured using automated hematocytometers, the main coagulation laboratory parameters and D-dimer level. RESULTS:The observational study indicate that children hospitalized with acute COVID-19-related illness have adult like coagulation changes, which significantly depend on the disease severity, presents of pneumonia and in the intensive care need cases, and the most sensitive indicator was the D-dimer level. However, there were opposite changes: both hyper- and hypocoagulation, a high frequency of normal or elevated platelet counts, as well as the presence of coagulopathy in 1/5 of cases even with a mild COVID-19 and the absence in 1/4 of severe cases. During the convalescence, coagulation laboratory parameters were normal, with the exception of an increased D-dimer level in every sixth patient within 1 month after recovery. CONCLUSIONS:Hemostasis changes in children with COVID-19-related illness differ from the adults by opposite, duration and risk factors. The anticoagulant therapy selection and duration requires an individual approach with the hematologist assistance. Further studies are needed to clarify the causes and consequences of hemostasis changes in children with mild forms of novel coronavirus SARS-CoV-2 infection, to establish additional coronavirus-associated coagulopathy factors in children with moderate and severe COVID-19, to develop recommendations for anticoagulant therapy in childhood.
- 18 April 2023
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (1) , 35-43
Open AccessHemostasis in children with COVID-19-RELATED illness
BACKGROUND:During the COVID-19 pandemic, the problem of coronavirus-associated coagulopathy was one of the most difficult and poorly studied. The detected hemostasis disorders in adults are extrapolated to children and adolescents without sufficient representation in the literature. Because of COVID-19 is generally told as a mild disease in children a detailed laboratory examination not required. As a result, thrombotic and hemorrhagic complications, as well as the childrens multisystem inflammatory syndrome (MIS-C) are unexpected. At the same time, the hemostasis assessment in children with COVID-19 is necessary for the coronavirus-associated coagulopathy timely diagnosis, adequate anticoagulant therapy prescribing, various convalescence thrombotic complications prevention, as well as determining the necessary period of dynamic monitoring of patients. AIM:To assess the hemostasis in children with COVID-19-related illness in the acute disease period and convalescence. MATERIALS AND METHODS:The results of the examination of 460 patients from 2 days to 18 years old hospitalized with confirmed SARS-CoV-2 infection and 110 outpatient children from 3 months to 17 years old at different periods of COVID-19 convalescence are presented. The study included platelet count measured using automated hematocytometers, the main coagulation laboratory parameters and D-dimer level. RESULTS:The observational study indicate that children hospitalized with acute COVID-19-related illness have adult like coagulation changes, which significantly depend on the disease severity, presents of pneumonia and in the intensive care need cases, and the most sensitive indicator was the D-dimer level. However, there were opposite changes: both hyper- and hypocoagulation, a high frequency of normal or elevated platelet counts, as well as the presence of coagulopathy in 1/5 of cases even with a mild COVID-19 and the absence in 1/4 of severe cases. During the convalescence, coagulation laboratory parameters were normal, with the exception of an increased D-dimer level in every sixth patient within 1 month after recovery. CONCLUSIONS:Hemostasis changes in children with COVID-19-related illness differ from the adults by opposite, duration and risk factors. The anticoagulant therapy selection and duration requires an individual approach with the hematologist assistance. Further studies are needed to clarify the causes and consequences of hemostasis changes in children with mild forms of novel coronavirus SARS-CoV-2 infection, to establish additional coronavirus-associated coagulopathy factors in children with moderate and severe COVID-19, to develop recommendations for anticoagulant therapy in childhood.
- 1 January 2022
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 57-61
Features of gastrointestinal disorders in children with multisystem inflammatory syndrome associated with COVID-19
Поражение ЖКТ является частью течения мультисистемного воспалительного синдрома у детей (МВС-Д), ассоциированного с новой короновирусной инфекцией COVID-19. По результатам ретроспективного исследования у детей с МВС-Д выявлено поражение ЖКТ, представленное такими признаками, как боль в животе, рвота, диарея и перитониальные симптомы. У этих детей отмечены значимые отличия в частоте встречаемости следующих признаков: гепатомегалия, спленомегалия, гипотония/шок, а также конъюнктивит и отёчность лица. Среди лабораторных отклонений более характерны гипоальбуминемия, но более высокий уровень СРБ и тропонина. В статье показано, что поражение ЖКТ является важным ранним предиктором тяжести...
- 1 January 2022
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 57-61
Features of gastrointestinal disorders in children with multisystem inflammatory syndrome associated with COVID-19
Поражение ЖКТ является частью течения мультисистемного воспалительного синдрома у детей (МВС-Д), ассоциированного с новой короновирусной инфекцией COVID-19. По результатам ретроспективного исследования у детей с МВС-Д выявлено поражение ЖКТ, представленное такими признаками, как боль в животе, рвота, диарея и перитониальные симптомы. У этих детей отмечены значимые отличия в частоте встречаемости следующих признаков: гепатомегалия, спленомегалия, гипотония/шок, а также конъюнктивит и отёчность лица. Среди лабораторных отклонений более характерны гипоальбуминемия, но более высокий уровень СРБ и тропонина. В статье показано, что поражение ЖКТ является важным ранним предиктором тяжести...
- Open Access
- 1 January 2017
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 16 (3) , 19-23
ACUTE STENOSING LARYNGOTRACHEITIS IN RESPIRATORY VIRAL INFECTIONS IN CHILDREN IN THE CLINICS OF ST. PETERSBURG
ОСТРЫЙ СТЕНОЗИРУЮЩИЙ ЛАРИНГОТРАХЕИТ ПРИ РЕСПИРАТОРНЫХ ВИРУСНЫХ МОНОИНФЕКЦИЯХ У ДЕТЕЙ, ГОСПИТАЛИЗИРОВАННЫХ В СТАЦИОНАРЫ САНКТ-ПЕТЕРБУРГА
- 1 January 2017
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 16 (3) , 19-23
Open AccessACUTE STENOSING LARYNGOTRACHEITIS IN RESPIRATORY VIRAL INFECTIONS IN CHILDREN IN THE CLINICS OF ST. PETERSBURG
ОСТРЫЙ СТЕНОЗИРУЮЩИЙ ЛАРИНГОТРАХЕИТ ПРИ РЕСПИРАТОРНЫХ ВИРУСНЫХ МОНОИНФЕКЦИЯХ У ДЕТЕЙ, ГОСПИТАЛИЗИРОВАННЫХ В СТАЦИОНАРЫ САНКТ-ПЕТЕРБУРГА